STOCKHOLM, Oct. 30, 2020 /PRNewswire/ -- Immunovia AB
announced today that the number of shares and votes in Immunovia
has changed due to a new share issue through the exercise of
warrants in the company. The warrants that have been exercised form
part of Immunovia's incentive program for senior executives and key
personnel as decided at the 2017 Annual General Meeting.
Through the registered shares after the new share issue, the
number of outstanding shares and votes increases by 28,500 from
22,603,081 to 22,631,581. The share capital increases by
SEK 1,425.00 from SEK 1,130,154.05 to SEK
1,131,579.05.
For more information, please contact:
Julie Silber, Director of
Investor Relations, Immunovia
Email: julie.silber@immunovia.com
Tel: +46 7 93 486 277
This information is such information that Immunovia is obliged
to publish in accordance with the Act (1991: 980) on trading in
financial instruments. The information was submitted, through the
care of the above contact person, for publication on October 30, 2020 at 09.00.
About Immunovia
Immunovia AB is a diagnostic company that is developing and
commercializing highly accurate blood tests for the early detection
of cancer and autoimmune diseases based on Immunovia's
proprietary test platform called IMMray™. Tests are based on
antibody biomarker microarray analysis using advanced
machine-learning and bioinformatics to single-out a set of relevant
biomarkers that indicate a certain disease. Thus, forming a unique
"disease biomarker signature".
The company was founded in 2007, based on cancer studies and
ground-breaking research in the Department of Immuntechnology at
Lund University and CREATE Health
Cancer Center, Sweden.
The first product, IMMray™ PanCan-d, is undergoing clinical
evaluation in some of the world's largest clinical studies for
pancreatic cancer, PanFAM-1, PanSYM-1 and PanDIA-1 and is
currently in the final validation phase. The company aims for a
sales start at the end of Q1 2021 with subsequent commercial
testing in Q2.
When validated, IMMray™ PanCan-d will be the first blood-based
test for early diagnosis of pancreatic cancer on the market, with a
potential to significantly improve patient survival and
outcome.
Immunovia Dx Laboratories located in Marlborough, Massachusetts, USA and
Lund, Sweden will provide
laboratory testing services in two accredited reference
laboratories.
Immunovia's shares (IMMNOV) are listed on Nasdaq Stockholm. For
more information, please visit www.immunovia.com.
This information was brought to you by Cision
http://news.cision.com
https://news.cision.com/immunovia-ab/r/change-in-the-number-of-shares-and-votes-in-immunovia-ab--publ-,c3228502
The following files are available for download:
https://mb.cision.com/Main/13121/3228502/1328316.pdf
|
Release
|
View original
content:http://www.prnewswire.com/news-releases/change-in-the-number-of-shares-and-votes-in-immunovia-ab-publ-301163734.html
SOURCE Immunovia AB